Monthly UpdateMay 12, 2026, 09:26 AM
bioAffinity Reports Record CyPath® Lung Unit Sales, +300% in April
AI Summary
bioAffinity Technologies, Inc. announced record monthly unit sales for its CyPath® Lung diagnostic test in April 2026. Sales for the noninvasive lung cancer detection test increased by nearly 300% compared to April 2025, based on preliminary unaudited data. This growth continues the trend of accelerating physician adoption and expanding clinical use, exceeding the company's internal projections. The company is focused on expanding adoption and advancing its technology platform with further clinical studies and an R&D pipeline for other respiratory diseases.
Key Highlights
- CyPath® Lung unit sales achieved a record high in a single month in April 2026.
- Unit sales for CyPath® Lung increased nearly 300% in April 2026 compared to April 2025.
- The growth continues the first quarter 2026 trend of accelerating adoption and clinical use.
- CyPath® Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, and 99% negative predictive value in a clinical trial.
- The company is advancing a large-scale longitudinal clinical study for CyPath® Lung.
- An R&D pipeline includes diagnostic tests for asthma and COPD.